Editorial
Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative
Annals of neurology
05/14/2026
DOI: 10.1002/ana.78246
PMID: 42132059
Abstract
To better understand the earliest stages of alpha-synucleinopathy, the Parkinson's Progression Markers Initiative (PPMI) has enrolled participants prior to the diagnosis of Parkinson's disease (PD) or dementia with Lewy Bodies (DLB). In this review, we describe lessons learned from prior enrollment and current strategies for PPMI eligibility. Severe hyposmia remains the strongest clinical predictor of aggregated synuclein as measured by a positive cerebrospinal fluid alpha-synuclein seed amplification assay (CSF aSyn SAA). CSF aSyn SAA is positive before dopamine transporter binding decreases, as measured by dopamine imaging. PPMI's adaptive eligibility criteria have enabled efficient identification of people in the early stage of neuronal synuclein disease defined by biomarkers alone and can inform future therapeutic studies. ANN NEUROL 2026.
Details
- Title: Subtitle
- Identification and Enrollment of Individuals Prior to Parkinson's Disease Diagnosis: Biomarker-Driven Adaptive Eligibility and Enrollment into the Parkinson's Progression Markers Initiative
- Creators
- Ethan G Brown - University of California, San FranciscoLana M Chahine - University of PittsburghRoseanne D Dobkin - Rutgers, The State University of New JerseyTanya Simuni - Northwestern UniversityTatiana Foroud - Indiana University School of MedicineLaura E A Heathers - Indiana University School of MedicineThomas F Tropea - Institute for Neurodegenerative DisordersCraig E Stanley Jr - Institute for Neurodegenerative DisordersBridget A McMahon - Institute for Neurodegenerative DisordersNorbert Brüggemann - University of LübeckChristine Klein - University of LübeckRonald B Postuma - Montreal Neurological Institute and HospitalNoah S Johnson - University of IowaCaroline Gochanour - University of IowaChelsea Caspell-Garcia - University of IowaRyan Kurth - University of IowaMichael C Brumm - University of IowaChristopher S Coffey - University of IowaKenneth Marek - Institute for Neurodegenerative DisordersCaroline M Tanner - University of California, San FranciscoParkinson's Progression Markers Initiative
- Resource Type
- Editorial
- Publication Details
- Annals of neurology
- DOI
- 10.1002/ana.78246
- PMID
- 42132059
- ISSN
- 1531-8249
- eISSN
- 1531-8249
- Publisher
- Wiley
- Grant note
- Michael J. Fox Foundation for Parkinson's Research AbbVie BIAL Critical Path Institute Edmond J. Safra Foundation Eli Lilly, Gain Therapeutics GE HealthCare Voyager Therapeutics Weston Family Foundation
PPMI - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including AbbVie, Alamar Biosciences, Aligning Science Across Parkinson's, Arrowhead Pharma, AskBio, BIAL, BioArctic, Biohaven, BlueRock Therapeutics, Bristol-MyersSquibb, Calico Labs, Capsida Biotherapeutics, Critical Path Institute, DaCapo Brainscience, Denali, Edmond J. Safra Foundation, Eli Lilly, Gain Therapeutics, GE HealthCare, Genentech, GSK, Insitro, Johnson & Johnson Innovative Medicine, Lundbeck, Merck, Neumora, Neuron23, Novartis, Regeneron, Roche, Sanofi, Tenvie, UCB, VanquaBio, Voyager Therapeutics, and the Weston Family Foundation.
- Language
- English
- Electronic publication date
- 05/14/2026
- Academic Unit
- Biostatistics
- Record Identifier
- 9985163459702771
Metrics
1 Record Views